Diana G. Santamaría-Domínguez, División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México
Jimena Pérez-Rubio, División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México
Ilse Y. Osorio-Aragón, División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México
María E. Vega-Memije, División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México
Rosa M. Lacy-Niebla, División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México
Mastocytosis is a rare clonal hematopoietic disorder characterized by the proliferation of neoplastic mast cells in the skin or other organs, including the bone marrow. It is classified into cutaneous, systemic, and mast cell sarcoma. Treatments focus on symptoms control or eliminating mast cells, with KIT inhibitors like midostaurin and avapritinib being effective therapies. Phototherapy has proven effective in symptomatic control in indolent systemic mastocytosis as in the presented case, improving quality of life.
Keywords: Systemic mastocytosis. Indolent. Phototherapy. Quality of life. Multisystem involvement. Mast cells.